U.S. markets closed

Recap: Fulgent Genetics Q4 Earnings

Benzinga Newsdesk

Fulgent Genetics (NASDAQ:FLGT) reported Q4 results.

Quarterly Results

• Earnings per share were up 500% over the past year to $0.04, which in line with the estimate.

• Revenue of $8,387,000 up by 47.68% from the same period last year, which missed the estimate of $8,510,000.

Conference Call Details

• Date: Mar 10, 2020

• Time: 8:05 PM ET

View more earnings on FLGT

• Webcast URL: https://edge.media-server.com/mmc/p/suwtghgd

Recent Stock Performance

• 52-week high was at $20.60

• 52-week low was at $4.71

• Price action over last quarter: Up 17.22%

Company Overview

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to a disease and enhanced disease treatment and prognosis.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.